Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma

Erik Ehinger, Jan Kopecky, Anna Darabi, Edward Visse, Charlotte Edvardsson, Gregor Tomasevic, David Cederberg, Mattias Belting, Johan Bengzon, Peter Siesjö

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients. Methods: Eight patients with newly diagnosed, histologically confirmed GBM were prescribed Salovum during concomitant radiochemotherapy. Safety was determined by the number of treatment-related adverse events. Feasibility was determined by the number of patients who completed the full prescribed Salovum treatment. Results: No serious treatment-related adverse events were observed. Out of 8 included patients, 2 did not complete the full treatment. Only one of the dropouts was due to issues directly related to Salovum, which were nausea and loss of appetite. Median survival was 23 months. Conclusions: We conclude that Salovum is safe to use as an add-on treatment for GBM. In terms of feasibility, adherence to the treatment regimen requires a determined and independent patient as the large doses prescribed may cause nausea and loss of appetite. Trial registration: ClinicalTrials.gov NCT04116138. Registered on 04/10/2019.

Original languageEnglish
Article number76
JournalBMC Neurology
Volume23
Issue number1
DOIs
Publication statusPublished - 2023

Subject classification (UKÄ)

  • Cancer and Oncology

Free keywords

  • Antisecretory factor
  • Glioblastoma
  • Novel treatments against glioblastoma
  • Salovum

Fingerprint

Dive into the research topics of 'Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma'. Together they form a unique fingerprint.

Cite this